BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Summit Corporation 



London      United Kingdom
Phone: n/a Fax: n/a


SEARCH JOBS




Industry
Biotechnology






 Company News
Summit Corporation Announces FDA Clearance Of IND Application For Phase 2 Study Of SMT19969 To Treat C. Difficile Infection 3/18/2014 9:15:51 AM    More...
Summit Corporation Announces First Patient Dosed In A Phase 1b Clinical Trial Of Smt C1100 For Treatment Of Duchenne Muscular Dystrophy 12/9/2013 11:07:48 AM    More...
Summit Corporation And The University of Oxford Enter Strategic Alliance To Develop Treatments For Duchenne Muscular Dystrophy 11/25/2013 12:22:00 PM    More...
Summit Corporation Awarded £2.4 Million From the UK Biomedical Catalyst Fund to Support the Development of DMD Therapy 7/31/2013 10:52:28 AM    More...
Summit Corporation Achieves Clinical Milestone Triggering £740,000 Payment From Wellcome Trust to Fund Novel C. Difficile Antibiotic 6/17/2013 9:03:49 AM    More...
Summit Corporation Outlines Clinical Development Plans for Utrophin Modulator Program for Duchenne Muscular Dystrophy 3/21/2013 12:10:04 PM    More...
Summit Corporation Forms Advisory Board to Support Development of Duchenne Muscular Dystrophy Program 2/13/2013 1:04:35 PM    More...
Summit Corporation and Children's National Medical Center Enter Utrophin Biomarker Collaboration for Duchenne Muscular Dystrophy 2/6/2013 10:31:46 AM    More...
Summit Corporation Release: Repeat Dosing of SMT C1100 for Treatment of Duchenne Muscular Dystrophy Meets Endpoints in Phase 1 Clinical Trial 11/7/2012 10:00:51 AM    More...
Summit Corporation Awarded Up to $3.6 Million From the Wellcome Trust to Support Clinical Development of Selective C. Difficile Antibiotic 10/22/2012 10:03:00 AM    More...
1234